ADMA Biologics (ADMA) Misses Q2 EPS by 1c

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $121.98 million versus the consensus estimate of $124.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• BT Brands posts Q2 profit, cuts costs as restaurant sales dip
• Jefferies on Pony AI Inc (PONY): 'overseas expansion is increasingly shifting toward JDM'